HAC is dedicated to connecting all patients and families affected by hATTR and wtATTR to the community and the resources they need. One of the ways we do this is through our advocacy efforts.

The Power of Advocacy

We want to empower patients, families, and caregivers, as well as members of the ATTR medical community to advocate to federal, provincial and territorial governments on issues that are important to our community. Your engagement in advocacy can help ensure that the amyloidosis community’s voice is heard, and needs are met by decision-makers.

Your Advocacy Efforts Lead to Access to Approved Therapies

For the first time, new therapies have been developed that treat the underlying cause of hATTR amyloidosis.

Thanks to efforts from the TAC community, three treatments – Tegsedi (inotersen), Onpattro (patisiran), and Vyndaqel–Tafamidis (Pfizer)  – are now accessible through publicly funded drug plans for patients who could benefit.

Sign up to Stay in Touch!

Get important updates, including Canadian-focused news and information about ATTR , delivered to your inbox.

*By submitting this form, you are consenting to receive emails from Hereditary Amyloidosis Canada. You can revoke your consent to receive emails at any time by using the unsubscribe link, found at the bottom of every email.